Evaluation of Copeptin in Patients With Cirrhosis and Ascites

The investigators wish to include prospectively 100 cirrhotic patients with ascites requiring prolonged hospitalization in the Hepato-gastroenterology departments of the Besançon, Nancy and Reims hospitals. The inclusion and follow-up periods will be six months each. At the inclusion of the patients we will evaluate the correlations between the plasma concentration of copeptin and 1 / the severity of cirrhosis (Child-Pugh and MELD scores) and serum sodium; 2 / systemic inflammation markers (CRP, leukocytes, IL-6 and lipopolysaccharides), 3 / calprotectin concentration in ascites. "

Inclusion criteria

• Man or woman
• Age between 18 and 80 years
• Acute decompensation of cirrhosis with occurrence of ascites
• Hospitalisationfor a complication of cirrhosis (first occurrence of ascites or recurrent ascites requiring hospitalization, gastrointestinal bleeding, hepatic encephalopathy, etc..)
• Patients participating to Ca-DRISLA study
• Information and Consent form signed

Exclusion criteria

• Pregnant or breastfeeding woman
• Age minor to 18 years
• Age major to 80 years
• Adult under protection law
• outpatients hospitalized for paracentesis
• ascites not related to portal hypertension (pancreatic ascites, peritoneal carcinosis…) Patients with hepatocellular carcinoma could be included